Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05144009 · ClinicalTrials.gov registry record · Phase 2
A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)
A Phase 2 study, sponsored by ADC Therapeutics S.A..
- Terminated
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT05144009 is a Phase 2 study that was terminated before completion, run by ADC Therapeutics S.A.. The registered enrollment target is 41 participants.
The verdict
NCT05144009, a Phase 2 study, was terminated before completion, sponsored by ADC Therapeutics S.A..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
The main objective of the trial is to assess the efficacy and tolerability of Lonca-R in unfit and frail participants with previously untreated DLBCL.
Interventions
- DRUG Rituximab
- DRUG Loncastuximab Tesirine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2022-06-21 |
| Est. Completion | 2024-01-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05144009
The ClinicalTrials.gov registry entry for NCT05144009 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ADC Therapeutics S.A., which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT05144009 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05144009 about?
NCT05144009 is a clinical study titled "A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)". The main objective of the trial is to assess the efficacy and tolerability of Lonca-R in unfit and frail participants with previously untreated DLBCL.
What is the current status of trial NCT05144009?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2022-06-21. Estimated completion is 2024-01-22.
What interventions are being tested in trial NCT05144009?
The interventions under investigation include: Rituximab (DRUG), Loncastuximab Tesirine (DRUG).
Who is sponsoring clinical trial NCT05144009?
This trial is sponsored by ADC Therapeutics S.A., which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.